Dr Camille Kotton outlines the risk of CMV in solid organ transplant recipients, preventative strategies, current antiviral treatment options and management of antiviral resistance1/3 Next Interview
Dr Razonable provides his perspectives on current treatment options for refractory and resistant CMV infection in solid organ transplant recipients2/3 Next Interview
Dr Papanicolaou considers best practice in the management of refractory and resistant CMV in solid organ transplant recipients, based on an example patient case3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, US-based experts discuss management challenges in solid organ transplant recipients with cytomegalovirus (CMV), the evolving antiviral options for refractory and resistant CMV, and best practice for the management of refractory/resistant CMV in these patients.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of infectious disease specialists, pulmonologists, gastroenterologists, transplant specialists involved in the management CMV infection in solid organ transplant recipients.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Camille Kotton discloses: Consulting fees from Biotest, Evrys, ExeVir, Hookipa, Merck, Oxford Immunotec and Takeda.
Dr Raymund Razonable discloses: Advisory board or panel fees from GlaxoSmithKline, Merck and Roche. Grants/research support from Gilead, Regeneron and Roche.
Genovefa Papanicolaou discloses Advisory board or panel fees from AlloVir, Amplyx, Octapharma and Vera. Consultancy fees from Astellas, Behring, Cidara, Merck & Co, Merck Sharp & Dohme, Octapharma, Partners RX, SymBio and Takeda. Grants/research support from Merck & Co and Takeda.
Sally Alrabaa, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Anne Nunn has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 5 September 2022. Date credits expire: 5 September 2023.
If you have any questions regarding credit please contact email@example.com.
After watching this activity, participants should be better able to:
- Explain the unmet needs of solid organ transplant recipients susceptible to cytomegalovirus (CMV)
- Discuss evolving antiviral options for solid organ transplant recipients with resistant or refractory (R/R) CMV
- Summarize best practice for the management of R/R CMV in solid organ transplant recipients